TCTai-Tsung Chang

Tai-Tsung Chang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tai-Tsung Chang has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Pei-Chin Lin

    2 shared publications
  • Pei‐Chin Lin

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

    2 shared publications
  • Yu‐Mei Liao

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

    2 shared publications
  • Bow-Wen Chen

    Division of Pediatric Hematology and Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan

    1 shared publication
  • Chao-Neng Cheng

    Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan

    1 shared publication
  • Chao-Ping Yang

    Department of Hematology-Oncology, Chang Gung Children’s Hospital-Linkou and Chang Gung University, Taoyüan, Taiwan

    1 shared publication

Latest Publications

  • Open Access

    Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan

    by Yung-Li Yang, Tang-Her Jaing, Shih-Hsiang Chen, Hsi-Che Liu, Iou-Jih Hung, Dong-Tsamn Lin, Chao-Ping Yang, Ching-Tien Peng, Kai-Hsin Lin, Chih-Cheng Hsiao, et al.

    Improvement in outcomes of children with acute myeloid leukemia (AML) is attributed to several refinements in clinical management. We evaluated treatment outcomes of Taiwanese pediatric AML patients in the past 20 years. Overall, 860 de novo AML patients aged 0–18 years and registered in the Childhood Cancer Foundation of R.O.C during January 1996–December 2019 were included. Survival analysis was performed to identify factors that improved treatment outcomes. Regardless of treatment modalities used, patients during 2008–2019 had better 5-year event-free survival (EFS) and overall survival (OS) rates than patients during 1996–2007. For patients received the TPOG-AML-97A treatment, only 5-year OS rates were significantly different between patients diagnosed before and after 2008. Patients with RUNX1–RUNX1T1 had similar relapse-free survival rates, but 5-year OS rates were better during 2008–2019. However, the survival of patients who received hematopoietic stem-cell transplantations (HSCT) did not differ significantly before and after 2008. For patients without relapse, the 5-year OS improved during 2008–2019. Non-relapse mortality decreased annually, and cumulative relapse rates were similar. In conclusion, 5-year EFS and OS rates improved during 2008–2019, though intensities of chemotherapy treatments were similar before and after 2008. Non-relapse mortality decreased gradually. Further treatment strategies including more intensive chemotherapy, novel agents’ use, identification of high-risk patients using genotyping and minimal residual disease, early intervention of HSCT, and antibiotic prophylaxis can be considered for future clinical protocol designs in Taiwan.


  • Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low‐dose regimens

    by Pei‐Chin Lin, Yu‐Mei Liao, Shih‐Pien Tsai, Tai‐Tsung Chang

    Background Inhibitory antibodies against infused clotting factor VIII concentrates (FVIII) developed in 20–30% of patients with hemophilia A. Bypass therapy may control the bleeds in patients with FVIII inhibitors, however, immune tolerance induction (ITI) therapy is the only proven modality for eradicating FVIII inhibitors. Since the cost of high-dose (200 IU/kg) ITI is extremely expansive, we conducted this study to identify whether low-dose ITI can be an alternative strategy besides high-dose ITI or bypass therapy. Procedure Patients with hemophilia A and FVIII inhibitors treated by ITI in Kaohsiung Medical University Hospital from January 2000 to January 2010 were enrolled. Regimens of ITI therapy included high-dose (100 IU/kg) and low-dose (30–50 IU/kg). Results High-dose ITI therapy for two high responders (HRs) and low-dose ITI therapy for three HRs and all low responders (LRs) were performed. Complete tolerance was achieved in 2 HRs with high-dose regimen, and in one HR and 19 LRs with low-dose regimens. We administered low-dose ITI combined with immune suppressants treatment for one of the patient with extremely high FVIII inhibitor titers and the inhibitor level markedly declined and no spontaneous bleeding episode was noticed during the treatment period. Conclusions The outcome of ITI in our study was satisfactory without clinically significant complications. Low-dose ITI regimens can effectively treat patients with high responder inhibitors, including one patient with extremely high inhibitor levels over 700 BU. Low-dose ITI may be an alternative modality for FVIII inhibitors management, especially in countries with limited resources. Pediatr Blood Cancer 2011; 57: 1029–1033.


  • Open Access

    Improved efficacy and tolerability of oral deferasirox by twice‐daily dosing for patients with transfusion‐dependent β‐thalassemia

    by Hsiu‐Hao Chang, Meng‐Yao Lu, Yu‐Mei Liao, Pei‐Chin Lin, Yung‐Li Yang, Dong‐Tsamn Lin, Shyh‐Shin Chiou, Shiann‐Tarng Jou, Kai‐Hsin Lin, Tai‐Tsung Chang

    Background: Deferasirox is an oral iron‐chelating agent taken once‐daily by patients with transfusion‐dependent iron overload. However, some patients are unresponsive or unable to tolerate once‐daily deferasirox. The current study evaluated whether twice‐daily deferasirox treatment showed increased efficacy or tolerability in unresponsive or intolerant patients.Procedure: Patients from two Taiwanese hospitals with transfusion‐dependent β‐thalassemia, including those who showed increasing serum ferritin levels for six consecutive months, with at least one level >2,500 ng/dl, while treated with >30 mg/kg/day of once‐daily deferasirox (unresponsive) or developed deferasirox‐related adverse events (AEs) at the dosage required to maintain the iron burden balance (intolerant) and were treated twice‐daily with the same total daily dose of deferasirox since 2008, were enrolled in the study and evaluated retrospectively by medical record review.Results: Eighteen patients were included for analysis. A statistically significant median decrease in serum ferritin levels was detected in the 11 unresponsive patients after 6 months of continuous twice‐daily deferasirox treatment. Five out of the seven intolerant patients experienced either no deferasirox‐related AEs or less severe AEs. The 12 patients from both groups (11 unresponsive, 1 intolerant) who received continuous twice‐daily deferasirox for 6 months showed a mild but significant median increase in serum creatinine levels.Conclusions: Twice‐daily deferasirox dosing is effective in iron chelation and improves tolerability in transfusion‐dependent β‐thalassemia patients who are unresponsive to or intolerant of once‐daily deferasirox. Future studies with greater patient numbers will be required to confirm the results reported herein. Pediatr Blood Cancer 2011;56:420–424.


    • 1 July 2003
      • Vol. 19  (7) , 368-74

    Hepatosplenic microabscesses in pediatric leukemia: a report of five cases.

    by Pei-Chin Lin, Tai-Tsung Chang, Ren-Chin Jang, Shyh-Shyn Chiou

    Hepatosplenic microabscesses secondary to invasion by various organisms may result in life-threatening conditions, especially in patients with cancer. Whether these patients should continue ongoing cytotoxic therapy, which might result in neutropenia, with the risk of progressive abscess formation or fungemia, remains a dilemma. We report five cases of pediatric acute leukemia with hepatosplenic microabscesses in children aged 4 years to 18 years. These patients presented with prolonged fever and neutropenia after antineoplastic chemotherapy, followed by abdominal pain, hepatosplenomegaly and hepatic dysfunction. Abdominal ultrasound and computed tomography (CT) or magnetic resonance imaging (MRI) demonstrated multiple small lesions compatible with hepatosplenic candidiasis in all of the patients. Cultures, including blood or stool cultures, were positive in only two cases. Treatment with intravenous antifungal agents, including amphotericin B, liposomal amphotericin B, and/or fluconazole were successful in two cases. These two patients remained event-free and survived for more than 24 months (20 months and 22 months after infection was diagnosed). The duration of systemic antifungal medication administration ranged from 3 months to 22 months. The serial image examinations revealed drastic reductions in small residual lesions in the two patients who survived the longest. The major issues for these patients were how long the antifungal therapy should be administered for, and how to select the optimal drug and dosage to avoid hepatic and renal toxicity. Among our patients, alternative therapy with amphotericin B, liposomal amphotericin B, and fluconazole was used according to the patients' conditions, and the duration of antifungal therapy was determined by clinical manifestations and imaging study changes.